Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Inter- and Intra-individual Variability of Anti-Xa Activity of Apixaban Versus Rivaroxaban Versus Control Arm During Non-valvular Atrial Fibrillation: Evaluation of Stability and Clinical Impact

NCT06862726 is registered in ClinicalTrials.gov with Les Laboratoires des Médicaments Stériles as lead sponsor.

NCT NCT06862726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06862726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Inter- and Intra-individual Variability of Anti-Xa Activity of Apixaban Versus Rivaroxaban Versus Control Arm During Non-valvular Atrial Fibrillation: Evaluation of Stability and Clinical Impact
Lead sponsor
Les Laboratoires des Médicaments Stériles
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
December 1, 2024
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non valvular atrial fibrillation